John H. van Duzer

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood · 2012 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy

Karen Krukowski, Jiacheng Ma, Olga Golonzhka et al. · Pain · 2017 · 187 citations

Medicine, Oncology, Pharmacology +13

Part I: Pathogenetic Role of Peroxynitrite in the Development of Diabetes and Diabetic Vascular Complications: Studies With FP15, A Novel Potent Peroxynitrite Decomposition Catalyst

Csaba Szabó, Jon G. Mabley, Suzanne M. Moeller et al. · Molecular Medicine · 2002 · 174 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability

Jeanine Jochems, Janette Boulden, Bridgin G. Lee et al. · Neuropsychopharmacology · 2013 · 169 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of Cathepsin B through Structure-Based Drug Design

Paul D. Greenspan, Kirk Clark, Rubén Tommasi et al. · Journal of Medicinal Chemistry · 2001 · 136 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15